Open Access

SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis

  • Authors:
    • Zijia Qin
    • Hang Tong
    • Tinghao Li
    • Honghao Cao
    • Junlong Zhu
    • Siwen Yin
    • Weiyang He
  • View Affiliations

  • Published online on: September 22, 2021     https://doi.org/10.3892/ijmm.2021.5037
  • Article Number: 204
  • Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sphingosine‑1‑phosphate (S1P) serves an important role in various physiological and pathophysiological processes, including the regulation of cell apoptosis, proliferation and survival. Sphingosine kinase 1 (SPHK1) is a lipid kinase that phosphorylates sphingosine to generate S1P. S1P has been proven to be positively correlated with chemotherapy resistance in breast cancer, colorectal carcinoma and non‑small cell lung cancer. However, whether SPHK1 is involved in the development of cisplatin resistance remains to be elucidated. The present study aimed to identify the association between SPHK1 and chemoresistance in bladder cancer cells and to explore the therapeutic implications in patients with bladder cancer. Bladder cancer cell proliferation and apoptosis were determined using Cell Counting Kit‑8 assays and flow cytometry, respectively. Apoptosis‑related proteins were detected via western blotting. The results revealed that SPHK1 was positively correlated with cisplatin resistance in bladder cancer cells, exhibiting an antiapoptotic effect that was reflected by the downregulation of apoptosis‑related proteins (Bax and cleaved caspase‑3) and the upregulation of an antiapoptotic protein (Bcl‑2) in SPHK1‑overexpression cell lines. Suppression of SPHK1 by small interfering RNA or FTY‑720 significantly reversed the antiapoptotic effect. A potential mechanism underlying SPHK1‑induced cisplatin resistance and apoptosis inhibition may be activation of STAT3 via binding non‑POU domain containing octamer binding. In conclusion, the present study suggested that SPHK1 displayed significant antiapoptotic effects in cisplatin‑based treatment, thus may serve as a potential novel therapeutic target for the treatment for bladder cancer.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 48 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Qin Z, Tong H, Li T, Cao H, Zhu J, Yin S and He W: SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis. Int J Mol Med 48: 204, 2021
APA
Qin, Z., Tong, H., Li, T., Cao, H., Zhu, J., Yin, S., & He, W. (2021). SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis. International Journal of Molecular Medicine, 48, 204. https://doi.org/10.3892/ijmm.2021.5037
MLA
Qin, Z., Tong, H., Li, T., Cao, H., Zhu, J., Yin, S., He, W."SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis". International Journal of Molecular Medicine 48.5 (2021): 204.
Chicago
Qin, Z., Tong, H., Li, T., Cao, H., Zhu, J., Yin, S., He, W."SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis". International Journal of Molecular Medicine 48, no. 5 (2021): 204. https://doi.org/10.3892/ijmm.2021.5037